private:yaupontherapeutics
|
1651483
|
Jun 4th, 2019 12:00AM
|
Yaupon Therapeutics, Inc
|
48
|
9.00
|
Open
|
Biotechnology
|
Jun 4th, 2019 03:26PM
|
Jun 4th, 2019 03:26PM
|
Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status.
|
Open
|
|
Open
|
259 Radnor Chester Road
|
Radnor
|
Pa
|
US
|
19087
|
|
Yaupon Therapeutics
|
|
Health Care Equipment & Services
|
private:yaupontherapeutics
|
1651483
|
Mar 26th, 2018 12:00AM
|
Yaupon Therapeutics, Inc
|
40
|
9.00
|
Open
|
Biotechnology
|
Mar 26th, 2018 04:52PM
|
Mar 26th, 2018 04:52PM
|
|
Open
|
|
|
|
|
|
|
|
|
Yaupon Therapeutics
|
|
Health Care Equipment & Services
|
private:yaupontherapeutics
|
1651483
|
Feb 17th, 2018 12:00AM
|
Yaupon Therapeutics, Inc
|
39
|
9.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status.
|
|
|
|
|
|
|
|
|
|
Yaupon Therapeutics
|
|
Health Care Equipment & Services
|
private:yaupontherapeutics
|
1651483
|
Feb 16th, 2018 12:00AM
|
Yaupon Therapeutics, Inc
|
39
|
9.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status.
|
|
|
|
|
|
|
|
|
|
Yaupon Therapeutics
|
|
Health Care Equipment & Services
|
private:yaupontherapeutics
|
1651483
|
Feb 15th, 2018 12:00AM
|
Yaupon Therapeutics, Inc
|
39
|
9.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status.
|
|
|
|
|
|
|
|
|
|
Yaupon Therapeutics
|
|
Health Care Equipment & Services
|
private:yaupontherapeutics
|
1651483
|
Feb 14th, 2018 12:00AM
|
Yaupon Therapeutics, Inc
|
39
|
9.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status.
|
|
|
|
|
|
|
|
|
|
Yaupon Therapeutics
|
|
Health Care Equipment & Services
|
private:yaupontherapeutics
|
1651483
|
Feb 13th, 2018 12:00AM
|
Yaupon Therapeutics, Inc
|
39
|
9.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status.
|
|
|
|
|
|
|
|
|
|
Yaupon Therapeutics
|
|
Health Care Equipment & Services
|
private:yaupontherapeutics
|
1651483
|
Feb 12th, 2018 12:00AM
|
Yaupon Therapeutics, Inc
|
39
|
9.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status.
|
|
|
|
|
|
|
|
|
|
Yaupon Therapeutics
|
|
Health Care Equipment & Services
|
private:yaupontherapeutics
|
1651483
|
Feb 11th, 2018 12:00AM
|
Yaupon Therapeutics, Inc
|
39
|
9.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status.
|
|
|
|
|
|
|
|
|
|
Yaupon Therapeutics
|
|
Health Care Equipment & Services
|
private:yaupontherapeutics
|
1651483
|
Feb 10th, 2018 12:00AM
|
Yaupon Therapeutics, Inc
|
39
|
9.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status.
|
|
|
|
|
|
|
|
|
|
Yaupon Therapeutics
|
|
Health Care Equipment & Services
|